These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22547623)

  • 41. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.
    Gumbo T; Sherman CM; Deshpande D; Alffenaar JW; Srivastava S
    Int J Infect Dis; 2021 Mar; 104():680-684. PubMed ID: 33556616
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.
    Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC
    Front Immunol; 2020; 11():680. PubMed ID: 32411131
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
    Veziris N; Ibrahim M; Lounis N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Am J Respir Crit Care Med; 2009 Jan; 179(1):75-9. PubMed ID: 18948422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
    Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.
    García-Rodríguez JF; Valcarce-Pardeiro N; Álvarez-Díaz H; Mariño-Callejo A
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2121-2126. PubMed ID: 31377953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.
    Veziris N; Ibrahim M; Lounis N; Andries K; Jarlier V
    PLoS One; 2011 Mar; 6(3):e17556. PubMed ID: 21408613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
    De Groote MA; Gruppo V; Woolhiser LK; Orme IM; Gilliland JC; Lenaerts AJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):731-8. PubMed ID: 22143517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
    Srivastava S; Deshpande D; Magombedze G; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S359-S364. PubMed ID: 30496465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New drugs for tuberculosis treatment.
    Sánchez F; López Colomés JL; Villarino E; Grosset J
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():47-56. PubMed ID: 21420567
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improving treatment outcome assessment in a mouse tuberculosis model.
    Mourik BC; Svensson RJ; de Knegt GJ; Bax HI; Verbon A; Simonsson USH; de Steenwinkel JEM
    Sci Rep; 2018 Apr; 8(1):5714. PubMed ID: 29632372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis.
    Montgomery SA; Young EF; Durham PG; Zulauf KE; Rank L; Miller BK; Hayden JD; Lin FC; Welch JT; Hickey AJ; Braunstein M
    PLoS One; 2018; 13(9):e0204495. PubMed ID: 30261007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
    Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
    J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Updates in the Treatment of Active and Latent Tuberculosis.
    Haas MK; Belknap RW
    Semin Respir Crit Care Med; 2018 Jun; 39(3):297-309. PubMed ID: 30071545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
    Gegia M; Cohen T; Kalandadze I; Vashakidze L; Furin J
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):812-6. PubMed ID: 22507372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Trends in tuberculosis treatment duration].
    Veziris N; Aubry A; Truffot-Pernot C
    Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.